Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?
- 10 October 2023
- journal article
- letter
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (4) , e171-e172
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81902379)
This publication has 8 references indexed in Scilit:
- AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantationJournal of Hepatology, 2023
- Evolving therapeutic landscape of advanced hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2022
- Hepatocellular carcinomaThe Lancet, 2022
- Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) ConsortiumGastroenterology, 2021
- Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantationHepatology International, 2021
- Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular CarcinomaAnnals of Surgery, 2020
- Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver TransplantationTransplantation, 2020
- Liver transplantation for hepatocellular carcinoma: Management after the transplantAmerican Journal of Transplantation, 2019